Active Placebo (Midazolam) Infusion

Phase 1

NNational and Kapodistrian University of Athens

Active Placebo (Midazolam) Infusion is one of 2 therapeutic programs targeting Cancer-related Pain. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cancer-Related PainRecruiting

Cancer-Related PainPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Cancer-Related Pain

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Phase 1

2 2

Active Placebo (Midazolam) Infusion

NNational and Kapodistrian University of Athens

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Cancer-Related Pain

NCT07408193

Clinical

Trials by Indication[1]

Cancer-related Pain1 trial

The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain: a Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Trial.

Recruiting·NNational and Kapodistrian University of Athens·Phase 1·NCT07408193·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Active Placebo (Midazolam) Infusion. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Active Placebo (Midazolam) Infusion. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National and Kapodistrian University of Athens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational and Kapodistrian University of Athens

Active Placebo (Midazolam) Infusion

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Cancer-related Pain1 trial

References

Drug Info

Quick Facts

Related News